The present invention relates to medicine and the pharmaceutical industry and describes the compositions of stable liquid drugs based on clofarabine intended for the treatment of cancer, including for the treatment of patients with refractory forms or relapses of acute leukemia: 1) a concentrate and 2) a solution intended for infusion introduction. The drug contains clofarabine in a concentration of 0.08-1.2 mg / ml, one- or two-substituted potassium or sodium phosphates in concentrations from 0.5 to 15.0 mg / ml, sodium chloride can be added to the composition to ensure the isotonicity of the drug in a concentration sufficient to achieve osmoticity of the solution in the range of 120-400 milliosmoles. The pH adjustment in the range of 5.5-8.0 for all proposed compositions of the composition is carried out by adding alkali metal hydroxide or phosphoric acid. The proposed composition of the drug concentrate based on clofarabine is characterized by increased stability, improved technology for the preparation of the finished drug. The composition also allows you to get a tool suitable directly for intravenous infusion, therefore, the aseptic conditions necessary for the preparation of a perfusion solution from a concentrate are not required and the possibility of medical personnel error in preparing a solution for infusion administration by diluting the concentrate is excluded.Настоящее изобретение относится к медицине и фармацевтической промышленности и описывает составы стабильных жидких лекарственных средств на основе клофарабина, предназначенных для лечения онкологических заболеваний, в том числе для лечения пациентов с рефрактерными формами или рецидивами острого лейкоза: 1) концентрат и 2) раствор, предназначенный для инфузионного введения. Лекарственное средство содержит клофарабин в концентрации 0,08-1,2 мг/мл, одно- или двухзамещенные фосфаты калия или натрия в концентрациях от 0,5 до 15,0 мг/мл, для обеспечения изотоничности лекарственного средства в состав м
